Item

Moderna is Developing Two New Vaccines-- And One Could Protect Against the Common Cold

Title (Dublin Core)

Moderna is Developing Two New Vaccines-- And One Could Protect Against the Common Cold

Description (Dublin Core)

This is a news story by health.com written by Alyssa Hui. This story is about Moderna expanding its biotechnology into creating new vaccines using similar techniques the COVID vaccines have used. One of these vaccines will be used to help combat RSV, which is a virus that hospitalizes an average of 177,000 adults per year, according to the CDC.

Another illness that Moderna is looking to use vaccines against are four other endemic human coronaviruses. Moderna does not claim they offer 100% guaranteed protection, but that they can benefit people greatly for reducing chances of contracting certain illnesses.

Moderna wants to ensure that the vaccines are safe and will go through testing procedures to do so. They are hoping that there will be more uses for mRNA style vaccines in the future, and not just for the coronavirus.

Date (Dublin Core)

April 15, 2022

Creator (Dublin Core)

Alyssa Hui

Event Identifier (Dublin Core)

HST580

Partner (Dublin Core)

Arizona State University

Type (Dublin Core)

Text story

Link (Bibliographic Ontology)

Controlled Vocabulary (Dublin Core)

English News coverage
English Science
English Healthcare

Curator's Tags (Omeka Classic)

Centers for Disease Control and Prevention
mRNA
vaccine
Respiratory Illnesses
research
HCoVs

Contributor's Tags (a true folksonomy) (Friend of a Friend)

Moderna
common cold
RSV
mRNA
science
vaccine

Linked Data (Dublin Core)

Date Submitted (Dublin Core)

04/16/2022

Date Modified (Dublin Core)

04/18/2022
04/26/2022
04/28/2022
08/02/2022

Item sets

This item was submitted on April 16, 2022 by [anonymous user] using the form “Share Your Story” on the site “A Journal of the Plague Year”: http://mail.covid-19archive.org/s/archive

Click here to view the collected data.

New Tags

I recognize that my tagging suggestions may be rejected by site curators. I agree with terms of use and I accept to free my contribution under the licence CC BY-SA